// App-Quantinova.ai

: Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

Researchers

Presenter

  • Mauricio Burotto

Principal Investigators

  • Bernard Escudier

  • Andrea B. Apolo

  • Maria Teresa Bourlon

  • Amishi Yogesh Shah

  • Cristina Suárez

  • Camillo Porta

  • Carlos H. Barrios

  • Martin Richardet

  • Howard Gurney

  • Elizabeth R Kessler

  • Yoshihiko Tomita

  • Jens Bedke

  • Saby George

  • Christian Scheffold

  • Peter Wang

  • Viktor Fedorov

  • Robert J. Motzer

  • Toni K. Choueiri

Medical Centers

  • Gustave Roussy, Villejuif, France

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • Bradford Hill Research Center, Santiago, Chile

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

  • 1.MD Anderson Cancer Center, Houston, TX

  • Eberhard Karls University, Tubingen, Germany

  • Centro de Hematologia e Oncologia, Porto Alegre, Brazil

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Westmead Hospital and Macquarie University, Sydney, Australia

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Barts Heart Centre, London, UK

  • University of Pavia, Pavia, Italy

  • Exelixis, Alameda, CA

  • Fundacion Richardet Longo, Instituto Oncologico de Cordoba, Cordoba, Argentina

  • University of Colorado Anschutz Medical Campus, Aurora, CO

Locations

  • Chile

  • Germany

  • Argentina

  • Italy

  • France

  • Japan

  • Mexico

  • Spain

  • Australia

  • United Kingdom

  • Brazil

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Cabozantinib

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03141177

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved